公开(公告)号：US11819543B2

公开(公告)日：2023-11-21

申请号：US17154536

申请日：2021-01-21

申请人： Qu Biologics Inc.

发明人： Harold David Gunn ,  Salim Dhanji ,  David W. Mullins

IPC分类号： A61K39/02 ,  A61K39/108 ,  A61K39/00

CPC分类号： A61K39/0266 ,  A61K39/0258 ,  A61K2039/521 ,  A61K2039/54 ,  A61K2039/541 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/57 ,  A61K2039/58 ,  Y02A50/30

摘要： The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.

公开(公告)号：US20230355751A1

公开(公告)日：2023-11-09

申请号：US18142216

申请日：2023-05-02

申请人： University of Southern California

发明人： Brad Spellberg ,  Travis Nielsen ,  Brian Luna

IPC分类号： A61K39/39 ,  A61K39/108 ,  A61K39/085 ,  A61K39/104 ,  A61K36/06 ,  A61K39/02 ,  A61K35/66

CPC分类号： A61K39/39 ,  A61K39/0266 ,  A61K39/085 ,  A61K39/1045 ,  A61K36/06 ,  A61K39/0258 ,  A61K39/104 ,  A61K39/025 ,  A61K35/66 ,  A61K2039/545

摘要： This disclosure provides a new vaccine composition and methods for its use. The composition contains an effective amount of each of: an aluminum hydroxide, a mono-phosphoryl lipid (MPL), and a whole glucan particles (WGP) but no an antigen that raises an immune response against a bacterial or fungal infection.

公开(公告)号：US20230338497A1

公开(公告)日：2023-10-26

申请号：US18004980

申请日：2021-07-08

申请人： VAXINANO

发明人： Didier Betbeder

IPC分类号： A61K39/108 ,  A61K9/19

CPC分类号： A61K39/0258 ,  A61K9/19 ,  A61K2039/55555

摘要： The field of extemporaneous preparation of vaccine compositions from lyophilized antigens. More specifically, the present disclosure relates to the use of cationic nanoparticles to render the lyophilized antigens more soluble without adding a lyophilization aid, with a view to extemporaneous use for administering a vaccine composition. In a particular embodiment, the present disclosure allows a vaccine formulation to be prepared or one or more valencies to be added to a previously formulated vaccine composition.

公开(公告)号：US11787841B2

公开(公告)日：2023-10-17

申请号：US17319006

申请日：2021-05-12

申请人： Inscripta, Inc.

发明人： Eric Abbate ,  Katherine Krouse ,  Richard Fox ,  Daniel Held ,  Michael Clay ,  Nandini Krishnamurthy

IPC分类号： A61K39/108 ,  C07K14/245

CPC分类号： C07K14/245 ,  A61K39/0258

摘要： The present disclosure relates to various different types of mutations in the thrA gene in E. coli leading to enhanced lysine production for, e.g., supplements and nutraceuticals.

公开(公告)号：US11655274B2

公开(公告)日：2023-05-23

申请号：US16900799

申请日：2020-06-12

申请人： Syddansk Universitet ,  Aarhus Universitet

发明人： Anders Boysen ,  Jakob Møller-Jensen ,  Giuseppe Palmisano ,  Martin Røssel Larsen

IPC分类号： C07K14/245 ,  A61K39/108

CPC分类号： C07K14/245 ,  A61K39/0258 ,  Y02A50/30

摘要： The present invention relates to glycosylated YghJ polypeptides from or derived from enterotoxigenic Escherichia coli (ETEC) that are immunogenic. In particular, the present invention relates to compositions or vaccines comprising the polypeptides and their application in immunization, vaccination, treatment and diagnosis of ETEC.

公开(公告)号：US20180353600A1

公开(公告)日：2018-12-13

申请号：US16062300

申请日：2016-12-21

申请人： INSTITUTE FOR RESEARCH IN BIO-MEDICINE

发明人： Fabio GRASSI ,  Michele PROIETTI

IPC分类号： A61K39/39 ,  A61K39/108 ,  A61K39/112 ,  A61K9/51 ,  A61P31/18 ,  A61P37/04

CPC分类号： A61K39/39 ,  A61K9/51 ,  A61K38/53 ,  A61K39/0258 ,  A61K39/0275 ,  A61K2039/55516 ,  A61K2039/57 ,  A61P31/18 ,  A61P37/04 ,  Y02A50/463 ,  Y02A50/465 ,  Y02A50/469 ,  Y02A50/471 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/481 ,  Y02A50/491

摘要： Compositions capable of enhancing and/or eliciting an immune response in a subject and methods of using the compositions. The compositions are capable of enhancing an IgA immune response and/or an IgG immune response and comprise an agent capable of reducing the level of binding of ATP to a P2X7 receptor to a subject. The compositions are for oral administration.

公开(公告)号：US09999600B2

公开(公告)日：2018-06-19

申请号：US15362476

申请日：2016-11-28

申请人： N-Fold LLC

发明人： Howard B. Sosin ,  Michael J. Caplan

IPC分类号： A61K9/51 ,  A61K39/35 ,  A61K9/50 ,  A61K39/02 ,  A61K39/145 ,  A61K39/39 ,  C12N7/00 ,  A61K39/108 ,  A61K39/00

CPC分类号： A61K9/5153 ,  A61K9/5031 ,  A61K9/5176 ,  A61K39/025 ,  A61K39/0258 ,  A61K39/145 ,  A61K39/35 ,  A61K39/39 ,  A61K2039/5258 ,  A61K2039/54 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55594 ,  A61K2039/57 ,  C12N7/00 ,  C12N2760/16034 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/394 ,  Y02A50/401 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/414 ,  Y02A50/416

摘要： The present invention provides, among other things, nanoparticle compositions including a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure defining an internal lumen and an external surface and one or more of a preparation of hydrophilic cellular components and a preparation of hydrophobic cellular components. In some embodiments, the preparation of hydrophilic cellular components is encapsulated within the internal lumen and the preparation of hydrophobic cellular components is associated with the external surface. Various methods of making and using disclosed nanoparticle compositions are also provided.

公开(公告)号：US09981027B2

公开(公告)日：2018-05-29

申请号：US15039697

申请日：2014-11-25

申请人： IDEMITSU KOSAN CO., LTD. ,  NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE

发明人： Kazutoshi Sawada ,  Takeshi Matsui ,  Eiji Takita ,  Takashi Hamabata ,  Toshio Sato

IPC分类号： A23K50/30 ,  A61K39/112 ,  C07K14/245 ,  C07K14/25 ,  A61K39/108 ,  A61K38/16 ,  A23K20/00 ,  A61K39/00

CPC分类号： A61K39/0283 ,  A23K20/00 ,  A23K50/30 ,  A61K38/164 ,  A61K39/0258 ,  A61K2039/542 ,  A61K2039/552 ,  C07K14/245 ,  C07K14/25 ,  C07K2319/00 ,  Y02A50/474

摘要： The present invention provides an agent for controlling colibacillosis including a fusion protein comprising a subunit of Shiga toxin and a subunit of Escherichia coli heat-labile toxin.

公开(公告)号：US20180117131A1

公开(公告)日：2018-05-03

申请号：US15802350

申请日：2017-11-02

申请人： VETERINARMEDIZINISCHE UNIVERSITAT WIEN

发明人： Michael Hess ,  Petra Ganas

IPC分类号： A61K39/002 ,  C12N1/36 ,  C12N1/20 ,  C12N1/10 ,  A61K39/108 ,  A61K39/00

CPC分类号： A61K39/002 ,  A61K39/00 ,  A61K39/0258 ,  C12N1/10 ,  C12N1/20 ,  C12N1/36

摘要： The invention discloses a method for producing a single bacterial strain culture of Histomonas meleagridis (H. meleagridis), the method being characterised by the following steps: (a) providing a xenic culture of H. meleagridis comprising H. meleagridis cells with a wild type bacterial flora, (b) treating the xenic culture with a mixture of antibiotics thereby killing the wild type bacterial flora, (c) centrifuging and washing the H. meleagridis cells, (d) controlling effectiveness of step (b), (e) resuspending the washed H. meleagridis cells, (f) adding one or more single bacterial strain(s) to the resuspended H. meleagridis cells, and (g) culturing the one or more single bacterial strain(s) with the resuspended H. meleagridis cells so as to obtain a single bacterial strain culture of H. meleagridis. The invention further discloses a vaccine formulation consisting of a Histomonas component consisting of an attenuated culture of Histomonas meleagridis, a bacterial component consisting of one or more cultures of a single bacterial strain, and pharmaceutically acceptable non-biological formulation compounds.

公开(公告)号：US09931390B2

公开(公告)日：2018-04-03

申请号：US15247297

申请日：2016-08-25

申请人： MONTANA STATE UNIVERSITY

发明人： David W. Pascual ,  Massimo Maddaloni

IPC分类号： A61K35/747 ,  A61K39/108 ,  A61K35/744 ,  A23L33/135 ,  A61K39/00

CPC分类号： A61K39/0258 ,  A23L33/135 ,  A23V2002/00 ,  A61K35/744 ,  A61K35/747 ,  A61K2039/523 ,  A61K2039/58 ,  Y02A50/474

摘要： The present disclosure relates generally to therapeutic compositions comprising recombinant bacteria. Further, the disclosure elaborates upon methods of utilizing the taught therapeutic compositions to treat autoimmune and inflammatory disease. The present teachings also relate to the disclosed recombinant bacteria and methods of producing the recombinant bacteria utilized in the compositions and methods. Further taught herein are dietary supplements and food additive compositions comprising the taught recombinant bacteria.